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Background
Acute myocardial infarction is one of the leading causes
of death in the world which is caused by coronary artery
thrombosis. Platelets play a central role in cardiovascu-
lar thrombosis. Platelet aggregation caused due to a rup-
tured artherosclerotic plaque could eventually lead to
vascular occlusion. Another important component of
vascular diseases is inflammation. During inflammation,
prostaglandins (PG) like PGI2,P G E 2 and PGD2 are
released which are also involved in thrombosis. Lower
concentrations of PGE2 enhance platelet aggregation
whereas higher concentrations inhibit aggregation. PGE2
acts via 4 receptors: EP1,E P 2,E P 3 and EP4 (Gs signal-
ling). The role of the EP3 receptor in enhancing platelet
activation and aggregation has been looked at in detail
but the role of the EP4 receptor is largely unknown. We
were interested in how this receptor modulates platelet
aggregation and what are the signalling mechanisms
involved in this process.
Methods
Platelet aggregation assays were performed ex vivo using
a platelet aggregation analyser (Aggregometer II). Blood
from healthy human donors was used to obtain platelet-
rich plasma. Aggregation was induced using ADP or
collagen. Different agonists and antagonists were added
to investigate their effects on platelet aggregation. Ca
2+
flux changes caused by addition of agonists were also
examined using a fluorescent Ca
2+ d y e( F l u o - 3 )b yf l o w
cytometry. Expression of the EP4 receptor on the surface
of platelets was established using indirect flow cytometry
whereas expression of CD62P, PAC1 and CD41 was
examined using direct flow cytometry. In vitro thrombus
formation was assessed by flowing whole blood on
collagen-coated Cellix biochips at −30 dyne/cm
2 using
the Mirus nanopump.
Results
We observed that human platelets express EP4 recep-
tors. A selective EP4 agonist potently inhibited the plate-
let aggregation as induced by ADP or collagen. This
effect could be completely reversed by using an EP4
antagonist, but not by PGI2,P G D 2 TXA2 receptor
antagonists. Moreover, an EP4 antagonist enhanced the
PGE2-induced stimulation of platelet aggregation, indi-
cating a potent anti-aggregatory activity of the EP4
receptors. Interestingly, the inhibitory effect of the EP4
agonist was brought about by protein kinase C but not
adenylyl cyclase, accompanied by attenuated Ca
2+ flux,
decreased activation of glycoprotein IIb/IIIa and down-
regulation of P-selectin. Most importantly, in vitro
thrombus formation was effectively reduced by the EP4
agonist and this effect was reversed using the EP4
antagonist.
Conclusions
These findings indicate that the EP4 receptor is a potential
biological drug target in anti-platelet therapy.
Published: 16 November 2010
doi:10.1186/1471-2210-10-S1-A17
Cite this article as: Philipose et al.: A biological target for antiplatelet
therapy: the prostaglandin E2 receptor EP4. BMC Pharmacology 2010
10(Suppl 1):A17.
* Correspondence: rufina.schuligoi@medunigraz.at
Institute of Experimental and Clinical Pharmacology, Medical University of
Graz, 8010 Graz, Austria
Philipose et al. BMC Pharmacology 2010, 10(Suppl 1):A17
http://www.biomedcentral.com/1471-2210/10/S1/A17
© 2010 Schuligoi et al; licensee BioMed Central Ltd.